# Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

> **NCT02168946** · PHASE3 · COMPLETED · sponsor: **Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)** · enrollment: 77 (actual)

## Conditions studied

- Urinary Tract Infection Complicated
- Acute Pyelonephritis
- Hospital Acquired Bacterial Pneumonia
- Ventilator-associated Bacterial Pneumonia
- Bacteremia
- Abdominal Infection

## Interventions

- **DRUG:** Vabomere
- **DRUG:** Best Available Therapy

## Key facts

- **NCT ID:** NCT02168946
- **Lead sponsor:** Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2017-07-21
- **Final completion:** 2017-07-21
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2019-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02168946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02168946, "Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02168946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*